Walden Biosciences is currently enrolling a Phase 2 clinical research study for people living with rare chronic kidney diseases READ MORE

News and
Investors

Filter
Sort by Date

Press Release

Walden Biosciences Announces Presentation at Antibody Engineering and Therapeutics Conference 2022

December 2, 2022

Press Release

Walden Biosciences Announces Participation at October Investor Conferences

October 13, 2022

Press Release

Walden Biosciences Appoints Peter Guest Linde, M.D. as Chief Medical Officer

October 11, 2022

Press Release

Walden Biosciences Announces Participation in Citi’s 17th Annual BioPharma Conference

August 31, 2022

Press Release

Walden Biosciences Announces Presentation at Canaccord Genuity 42nd Annual Growth Conference

August 4, 2022

Press Release

Walden Biosciences Announces Research Collaboration with University of Michigan

July 5, 2022